Takeda logo

Takeda Oncology Pipeline: Investigational Therapies for Cancer Treatment | Takeda Oncology

Our Pipeline

Our Pipeline

Our oncology R&D activities are focused on translating science into curative or transformative potential treatments through novel strategies that leverage the untapped power of innate immunity.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

Investigational therapyPlatformInvestigational indicationPhase
Plus

Cabozantinib*

Targeted therapy

Metastatic castration-​resistant prostate cancer (JP)

Phase 3

Plus

Fruquintinib*

Targeted therapy

Previously treated metastatic colorectal cancer (EU, JP)

Filed

Plus

Ixazomib*

Proteasome inhibitor

Maint. newly diagnosed multiple myeloma post- stem cell transplant (US, EU)

Phase 3

Plus

Ponatinib*

Targeted therapy

Newly Diagnosed Ph+ acute lymphocytic leukemia (US)

Phase 3

Targeted therapy

Pediatric Ph+ acute lymphoblastic leukemia

Phase 1

Plus

Relugolix* (TAK-385)

Small molecule

Prostate cancer (JP, Asian countries)

Phase 3

Plus

Dazostinag (TAK-676)

Innate immunity enhancer

Solid tumors

Phase 1/2

Plus

Subasumstat (TAK-981)

Innate immunity enhancer

Multiple cancers

Phase 1/2

Plus

TAK-007

Redirected immunity

B-cell malignancies

Phase 2

Plus

TAK-012

Redirected immunity

Acute myeloid leukemia

Phase 1/2a

Plus

TAK-186

Redirected immunity

Solid tumors

Phase 1/2

Plus

TAK-280

Redirected immunity

Solid tumors

Phase 1/2

Plus

TAK-500

Innate immunity enhancer

Solid tumors

Phase 1/2

  • *Marketed products have received approval in one or more jurisdictions.

  • All programs have global development rights unless otherwise noted.

  • GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets

Investors

To learn more about Oncology-specific Investor events and information, visit the Takeda Oncology Investor Relations page

Explore IR
Banner Image

Explore More

Card image

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline.
Card image

Partnership Strategy

We believe the best way to achieve our aspiration to cure cancer is by working together.
Newsroom

Newsroom

Keep up on the latest Oncology news by visiting our newsroom.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23